1. The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan.
- Author
-
Lin, Chih‐Lin, Tai, Chi‐Ming, Huang, Jee‐Fu, Liu, Chun‐Jen, Chen, Hui‐Fen, Cheng, Pin‐Nan, Chen, Chi‐Yi, Peng, Cheng‐Yuan, Wang, Chia‐Chi, Weng, Shih‐Han, Tseng, Tai‐Chung, and Kao, Jia‐Horng
- Subjects
NON-alcoholic fatty liver disease ,BODY mass index ,LEAN body mass ,HEPATIC fibrosis ,CLINICAL pathology - Abstract
Background and Aim: The aim of this study was to assess the impact of body mass index (BMI) on the clinical and histological characteristics of patients with nonalcoholic fatty liver disease (NAFLD). Methods: Patients with clinically diagnosed NAFLD who received liver biopsy were retrospectively enrolled from 2007 to 2019. For comparison, all of the patients were divided into lean body mass (< 23 kg/m2), overweight (23–24.9 kg/m2), and obesity (BMI ≧ 25 kg/m2). Results: A total of 572 patients with histologically confirmed NAFLD, including 40 (6.99%) lean body mass, 54 (9.44%) overweight, and 478 (83.57%) obese patients, were recruited. Obese NAFLD patients had significantly higher grade of steatosis (grade 3: 29.92% vs 22.22% vs 12.5%, P < 0.0001) and hepatocyte ballooning (grade 2: 14.85% vs 12.96% vs 12.5%, P < 0.0001) than overweight and lean NAFLD patients. The prevalence of nonalcoholic steatohepatitis (NASH) was 22.5%, 25.93%, and 36.19% in lean, overweight, and obese NAFLD patients, respectively. Obesity was significantly associated with fibrosis severity (P = 0.03). The fibrosis index based on four factors (FIB‐4) score can identify NAFLD patients without significant fibrosis or with cirrhosis. The areas under the receiver‐operating characteristic curve of FIB‐4 score to identify patients without significant fibrosis or with cirrhosis were 0.82 (95% confidence interval [CI]: 0.69–0.96) and 0.87 (95% CI: 0.76–0.99) in lean patients; 0.77 (95% CI: 0.61–0.93) and 0.81 (95% CI: 0.59–1.0) in overweight patients; and 0.77 (95% CI: 0.72–0.82) and 0.89 (95% CI: 0.85–0.92) in obese patients. Conclusions: The majority of NAFLD patients are obese, as defined by BMI. Obesity was significantly associated with NASH and hepatic fibrosis severity in patients with NAFLD. In the present study, we demonstrated that the prevalence of nonalcoholic steatohepatitis (NASH) was higher in obese NAFLD patients than in those with lean and overweight NAFLD. Histologically, obese NAFLD patients had significantly higher grade of steatosis and hepatocyte ballooning than lean and overweight NAFLD patients. Moreover, the fibrosis index based on four factors (FIB‐4) score had good values of area under receiver‐operating characteristic curves to identify NAFLD patients without significant fibrosis or with cirrhosis, irrespective the body mass index. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF